新华社长沙9月26日电 题：产业规模近万亿元 中国生物制造如何竞逐"新蓝海"？ 新华社记者唐诗凝 大豆经生物酶转化，成为保健品市场的新宠；玉米变身燃料乙醇，助力减少航空业碳排放；利用基 因工程菌株生产的胰岛素，成为治疗糖尿病的有效手段……在我国，生物制造正成为产业创新发展 的"新赛道"。 "中国的生物制造产业总规模已接近1万亿元。"工业和信息化部消费品工业司司长何亚琼在2025中 国生物制造科技创新论坛上说，科技创新和产业创新融合发展，正带动一批有竞争力的生物制造产业集 聚区逐步成长壮大。 9月25日至26日，2025中国生物制造科技创新论坛在湖南常德举行。来自全国的知名专家、创新企 业家和投融资机构代表等齐聚一堂，共话生物制造领域新技术、新机遇。 生物制造是一种新兴的生产技术，通过生物过程来合成或加工产品，与传统的化学或物理制造方法 相比，具有绿色、高效、可再生等特点。 "生物制造是科技创新和产业创新融合发展的重要领域""生物制造具有引领'第四次工业革命'的潜 力"……论坛上，与会嘉宾们纷纷表示，伴随生物制造快速发展，不断迭代的技术创新对新产业、新模 式、新动能的催生带动作用显著增强。 慕恩广州（生物）科技 ...

Core Viewpoint - The article discusses the rapid development and potential of the biomanufacturing industry, highlighting its role in the Fourth Industrial Revolution and the significant growth opportunities it presents in various sectors, particularly in China [3][4]. Industry Overview - Biomanufacturing is defined as an advanced production method centered on industrial biotechnology, utilizing biological resources and processes to produce target products at scale [5]. - The global biomanufacturing industry is projected to reach approximately $12,190 billion in 2024, with a year-on-year growth of 7.4%, and is expected to exceed $20 trillion by 2030, with a compound annual growth rate (CAGR) of 8.4% [9]. Market Dynamics - In China, the biomanufacturing industry is anticipated to reach a scale of 1.01 trillion yuan in 2024, growing by 15.4%, and is expected to surpass 2.5 trillion yuan by 2030, with a CAGR of 16.8% [9][10]. - The top three segments in China's biomanufacturing industry in 2024 will be biopharmaceuticals, biological food, and bio-chemical products, with biopharmaceuticals remaining the largest segment [10]. Technological Advancements - The industry is experiencing a shift from traditional resource reliance to technology-driven approaches, with significant improvements in biomass resource utilization and equipment efficiency [8]. - Innovations in biopharmaceuticals, such as the development of bispecific antibodies and ADC drugs, have seen an annual growth of 65% in product pipelines [8][12]. Application and Impact - In the medical field, biomanufacturing technologies like 3D printing are enabling personalized implants, achieving gross margins of 75% [9]. - In agriculture, microbial fertilizers have improved corn yields by 12% while reducing chemical fertilizer usage by 30% [9]. Future Trends - The article outlines several key trends, including the restructuring of industrial ecosystems, regional layout changes, deepening technological revolutions, product innovation iterations, and capital factor restructuring [17][18][19]. - The integration of AI and biotechnology is expected to enhance production efficiency and product quality, with significant implications for the industry [18]. Strategic Recommendations - Companies are encouraged to build a three-dimensional competitive system focusing on technology research and development, scene innovation, and ecosystem construction [20]. - Local governments should create a supportive industrial service matrix to foster the growth of the biomanufacturing sector [20].

Core Insights - The article highlights the establishment and growth of Zhongke Arno Biotechnology Co., Ltd., which has become a model for synthetic biology manufacturing in China, particularly in the Guangming Science City [1][3] Company Overview - Zhongke Arno has developed a 3,300 square meter vertical factory that integrates research, production, and sales, representing the largest synthetic biological reactor in Guangming District [1][3] - The company has achieved the first and only production license for naked algae products in China since the material was included in the national new food raw material directory in 2013, and has successfully entered mass production [3] Industry Context - The company operates in the synthetic biology sector, focusing on high-value biological active substances and biomedical materials, particularly in areas such as anti-aging, anti-tumor, and immune enhancement [3] - The establishment of the company aligns with national strategic priorities, contributing to the self-sufficiency of China's high-end biological manufacturing supply chain by achieving import substitution in multiple fields [3] Entrepreneurial Journey - The founder, Chen Yang, transitioned from academia to entrepreneurship, motivated by the rapid growth of synthetic biology enterprises in Shenzhen and the supportive environment for innovation in Guangming Science City [2][4] - The company emphasizes a flexible employment and entrepreneurship support platform called "Smart Mulan," aimed at empowering more women in technology [4] Team Composition - The company boasts a young team with an average age in the 30s, comprising 77% research and development personnel and 91% with high academic qualifications, positioning itself to compete with leading global enterprises [4]